Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q4 FY25 results · Jan–Mar 2025
Astec LifeSciences reported revenue from operations of ₹119.53 crore (down 22.3% from Q4 FY24) and net loss of ₹16.08 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.53 | 153.75 | −22.3% | 93.86 | +27.3% |
| Other income | 0.79 | 2.05 | −61.4% | 1.91 | −58.7% |
| Total income | 120.32 | 155.80 | −22.8% | 95.77 | +25.6% |
| Profit before tax | (15.66) | (0.93) | Loss widened | (25.15) | Loss narrowed |
| Net profit for the period | (16.08) | (0.96) | Loss widened | (40.37) | Loss narrowed |
| Attributable to shareholders of the company | (16.09) | (0.97) | Loss widened | (40.38) | Loss narrowed |
| EPS, basic (₹) | (8.20) | 0.50 | Turned loss | (20.59) | Loss narrowed |
| Net margin (%) | -13.5 | -0.6 | -43.0 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.53 | 153.75 | −22.3% | 93.86 | +27.3% |
| Other income | 0.78 | 2.03 | −61.7% | 1.89 | −58.9% |
| Total income | 120.30 | 155.78 | −22.8% | 95.75 | +25.6% |
| Profit before tax | (15.69) | (0.96) | Loss widened | (25.18) | Loss narrowed |
| Net profit for the period | (16.10) | (0.99) | Loss widened | (40.40) | Loss narrowed |
| EPS, basic (₹) | (8.21) | 0.50 | Turned loss | (20.60) | Loss narrowed |
| Net margin (%) | -13.5 | -0.6 | -43.0 |
Consolidated
- Filed with BSE
- 09 May 2025, 14:33 IST
- Board meeting
- 23 Apr 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 May 2025, 14:33 IST
- Board meeting
- 23 Apr 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE